Takeda divests Alzheimer's candidate to Japanese academic partner
This article was originally published in Scrip
Takeda has decided to transfer an early-stage candidate for Alzheimer's disease to an academic partner in Japan for development, reflecting selectivity about which R&D projects the firm focuses on in-house given wider business pressures.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.